Axitinib as Second-line Treatment for Advanced Hepatocellular Carcinoma
NCT01273662
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
45
Enrollment
OTHER
Sponsor class
Conditions
Hepatocellular Carcinoma
Interventions
DRUG:
AG-013736
Sponsor
National Taiwan University Hospital
Collaborators
[object Object]
[object Object]